Robotic Bronchoscopy for Peripheral Pulmonary Lesions: A Multicenter Pilot and Feasibility Study Save

Date Added
June 12th, 2018
PRO Number
Pro00077962
Researcher
Gerard Silvestri

Silhouette
Keywords
Cancer, Lung, Pulmonary
Summary

Physicians currently have difficulty getting a biopsy of lung spots that are far out from the center of the lung. The bronchoscopes that are used to reach these spots currently are sometimes difficult to maneuver and are unable to reach far to these spots because of the large size of the bronchoscope. This study will test a new robotic scope that uses navigation software to find the distant spots in the lung so physicians can get a biopsy.

Institution
MUSC
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F) Save

Date Added
June 12th, 2018
PRO Number
Pro00078198
Researcher
Patrick Flume

Silhouette
Keywords
Cystic Fibrosis, Lung, Pediatrics, Pulmonary
Summary

The purpose of this study is learn more about the effectiveness and safety of VX-445 used in combination with TEZ, IVA and VX-561 in patients with cystic fibrosis.
Participation could last for approximately 16 weeks. This will include a Screening Period that will last up to 4 weeks, a Run-in Period that will last up to 4 weeks, a Treatment Period that will last up to 4 weeks, and a Follow-up Period that may last up to 4 weeks after the last dose of Study Drug. Approximately 100 people will participate in this study.

Institution
MUSC
Recruitment Contact
Robyn Do
(843) 792-1221
dorobyn@musc.edu

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) Save

Date Added
May 22nd, 2018
PRO Number
Pro00078126
Researcher
Patrick Flume

Silhouette
Keywords
Cystic Fibrosis, Lung, Pediatrics, Pulmonary
Summary

The purpose of this study is to learn more about the effectiveness and safety of VX-445 used in combination with TEZ and VX-561 in patients with cystic fibrosis. Participation could last for approximately 32 weeks. This will include a Screening Period that will last up to 4 weeks, a Treatment Period that will last up to 24 weeks, and a Follow-up Period that may last up to 4 weeks after the last dose of Study Drug. Approximately 360 people will participate in this study.

Institution
MUSC
Recruitment Contact
Robyn Do
(843) 792-1221
dorobyn@musc.edu

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis Save

Date Added
May 22nd, 2018
PRO Number
Pro00078211
Researcher
Patrick Flume

Silhouette
Keywords
Cystic Fibrosis, Lung, Pulmonary
Summary

In this study, PTI-808 will be given alone and in combination with two other experimental drugs, PTI-801 and PTI-428. PTI-428, PTI-801, and PTI-808 are considered cystic fibrosis transmembrane conductance regulator (CFTR) modulators being developed to treat the underlying mechanism of cystic fibrosis. PTI-428 is a CFTR amplifier that increases the amount of CFTR protein in the cell, PTI-801 is a CFTR corrector that improves the processing of CFTR protein in the cell, and PTI-808 is a CFTR potentiator to enhance the activity of CFTR at the cell surface. Individual modulators have been shown to have limited activity, and therefore it is predicted that a combination of modulators will be required to fully address the CFTR protein defects. The study will also obtain information on how the study drug moves into, through, and out of the body. The expected duration of this study is up to 57 days

Institution
MUSC
Recruitment Contact
Abbi Reed
843-792-1820
reedab@musc.edu

Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease Save

Date Added
May 8th, 2018
PRO Number
Pro00077568
Researcher
Richard Silver

Silhouette
Keywords
Autoimmune disease, Drug Studies, Lung, Scleroderma, Shortness of Breath
Summary

This study will assess how 18 months of oral mycophenolate will compare to 18 months of mycophenolate plus pirfenidone, in the treatment of Systemic Sclerosis related Interstitial Lung Disease. Tolerability and toxicity will also be assessed, during this study.
This research is designed to test whether combining pirfenidone and mycophenolate will result in a more rapid and possibly greater improvement in lung function than occurs when mycophenolate is used alone. While both of these drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat other medical conditions, neither drug has been FDA-approved for the treatment of scleroderma related lung disease. This research is being funded by the drug company, Genentech.

Institution
MUSC
Recruitment Contact
Kelley Kajdasz
843-792-5290
gibsonke@musc.edu

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma." Save

Date Added
April 24th, 2018
PRO Number
Pro00076862
Researcher
John Wrangle

Silhouette
Keywords
Cancer, Cancer/Lung, Lung
Summary

This study is for patients that have been diagnosed with mesothelioma. This study is to test whether giving one drug, atezolizumab, along with cisplatin and pemetrexed, before surgery and atezolizumab after surgery by vein is safe. Atezolizumab is the experimental cancer drug in this study, which has already been approved for the treatment of patients with bladder cancer and lung cancer. Participants can expect to be in this study for up to a year and followed for side effect for up to three years after study completion.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation Save

Date Added
March 27th, 2018
PRO Number
Pro00075578
Researcher
Sylvia Szentpetery

Silhouette
Keywords
Cystic Fibrosis, Lung, Pediatrics, Pulmonary
Summary

The purpose of this study is to learn more about the long-term safety, tolerability, and effects of the combination of VX-661 and ivacaftor in subjects with Cystic Fibrosis. This is a rollover study from study VX 15-661-113 Part B. Approximately 121 people will participate in this study. Participation could last for approximately 100 weeks. This will include a treatment period that will last up to 96 weeks, and a follow-up period that will last up to 4 weeks.

Institution
MUSC
Recruitment Contact
Abbi Reed
(843) 792-1820
reedab@musc.edu

Key informant interviews to facilitate development of adherence tools in solid organ transplant Save

Date Added
March 15th, 2018
PRO Number
Pro00075735
Researcher
Nicole Pilch

Silhouette
Keywords
Heart, Kidney, Liver, Lung, Non-interventional, Transplant
Summary

A sample of patients will be drawn from a cross-sectional cohort of pre- and post-abdominal and cardiothoracic transplant recipients from March 2018 through May 2018. 10 to 15 minute key informant interviews will be conducted with patients to ascertain their views and perceptions related to adherence pre- and post-transplant and use of technolgy. This data will be used to educate the transplant community about adherence from the patient's perspective.

Institution
MUSC
Recruitment Contact
Nicole Pilch
843-792-3702
weimert@musc.edu

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis Save

Date Added
February 27th, 2018
PRO Number
Pro00075593
Researcher
Patrick Flume

Silhouette
Keywords
Cystic Fibrosis, Lung, Pediatrics, Pulmonary
Summary

This is a research study to find out if a drug called lenabasum can help people with Cystic Fibrosis (CF) and if it is safe to take without causing too many side effects. There are 9 planned study visits in the institution during this study.

Institution
MUSC
Recruitment Contact
Abbi Reed
(843) 792-1820
reedab@musc.edu

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (iNO) IN SUBJECTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS ON LONG TERM OXYGEN THERAPY (PART 1 AND PART 2) Save

Date Added
January 23rd, 2018
PRO Number
Pro00074258
Researcher
Rahul Argula

Silhouette
Keywords
Lung, Pulmonary
Summary

The purpose of this study is to determine if the study drug, inhaled nitric oxide, when given and breathed through an investigational study device called the INOpulse, may help treat PF. Inhaled nitric oxide is a drug approved by the FDA and Health Canada for the treatment of infants who have difficulty breathing and have decreased oxygen in their blood associated with pulmonary hypertension. Inhaled nitric oxide and the INOpulse delivery device are investigational for the treatment of PF with and without pulmonary hypertension and are not currently an approved treatment. Because we do not know if this drug and device combination will treat PF, we need to compare it against a placebo (a pretend drug that has no effect on a person). To do this, we will put people taking part in this study into two groups. The groups are selected by chance, like a coin toss. Participants in one group will be given the study drug while participants in the other group will be given the pretend drug.

Institution
MUSC
Recruitment Contact
Jordyn DeMartino
(843) 792-8092
demartij@musc.edu

Change_preferences

-- OR --

Create_login